|
|
|||||||||
|
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail. Erratum: Vol. 42, No. RR-7In the MMWR Recommendations and Reports, "Initial Therapy for Tuberculosis in the Era of Multidrug Resistance, Recommendations of the Advisory Council for the Elimination of Tuberculosis," dated May 21, 1993, on page 3, Option 1 in Table 1 should read as follows: Administer daily INH, RIF, and PZA for 8 weeks followed by 16 weeks of INH and RIF daily or 2-3 times/week *. In areas where the INH resistance rate is not documented to be less than 4%, EMB or SM should be added to the initial regimen until susceptibility to INH and RIF is demonstrated. Continue treatment for at least 6 months and 3 months beyond culture conversion. Consult a TB medical expert if the patient is symptomatic or smear or culture positive after 3 months. In addition, add the following citation to the reference section: 17. CDC. National action plan to combat multidrug-resistant tuberculosis. MMWR 1992;41(no. RR-11):1-30. Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices. **Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.Page converted: 09/19/98 |
|||||||||
This page last reviewed 5/2/01
|